ISB is a derivation of the IS performed in initial diagnostic biopsies before nCRT that has the advantage of evaluating the effect of the initial immune infiltrate (CD3+ and CD8+ T cells in the tumor) on response to nCRT and clinical outcome. Here, CD8A is linked to neoplasm.